AzTrials
AzTrials

Breast CancerMISSNCT04590560

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?

A study testing screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice in people with Breast Cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS at 4 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high… Read more about this study

Who is it for?
Ages 45 to 49 years, women only
Conditions the study is for
Breast Cancer
What is being tested?
screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60,000 participants
Where
4 sitesItaly
Study dates
6 Feb 2020to Feb 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 49 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women invited for their first or second mammography (45 or 46 y/o) presenting for screening;
  • Willingness and ability to comply with scheduled visits;
  • Written informed consent obtained prior to performing any protocol-related procedures.

Who cannot join

  • Pregnancy status;
  • Personal history of prior breast carcinoma, either invasive or ductal carcinoma in situ (DCIS) diagnosis;
  • Ascertained heredo-familial risk according to the standard family history used in screening programs;
  • Participation in another clinical trial on BC screening;
  • Inability to provide signed informed consent.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Chiara Zingaretti contact

cc.ubsc@irst.emr.it

Italy4 sites, 4 recruiting
  • Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO)

    Florence

    Marco Zappa, MD

    Paola Mantellini, MD

    Not yet recruiting
  • AUSL Romagna

    Forlì

    Fabio Falcini, MD

    Recruiting
  • Irst Irccs

    Meldola (FC), FC, 47014

    Fabio Falcini, MD

    Recruiting
  • AOU Città della Salute e della Scienza

    Torino

    Livia Giordano, MD

    Not yet recruiting

Other trials in Italy

About this study

Official title: What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer

Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.

Read the detailed description

According to the 2006 European guidelines, the target age for mammography screening is 50-69 years. For women aged 40-49, effectiveness is less and less certain. For those over 70, the most important concern is overdiagnosis. In Europe, so far, both age groups have been invited to screen only in a few countries and regional areas, including some Italian regions. Recently, new European guidelines have been published, developed in the framework of the European Commission Initiative on Breast Cancer. Although with caution, they recommend screening for both women aged 45-49 and those aged 70-74. The recommended interval is 2 or 3 years in the first case and 3 years in the second. The quality of the evidence on which these recommendations are based is defined as very low. Particularly for women aged 45-49, the new European guidelines indicate the need for a research effort, based on comparative studies, on the effectiveness of different screening intervals. This responsibility also falls on Italy, which is the only European country where women aged 45-49 are invited on an annual basis. Therefore, a research project is proposed which includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.

To define the best interval for screening women 45-49 years old a three-arm multicenter randomized non-inferiority trial will be conducted. Women signing the written informed consent will be randomized with a 1:1:1 ratio to:

Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (Breast Imaging-Reporting and Data System -BI-RADS- category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (Breast Imaging-Reporting and Data System -BI-RADS- category A, B, C).

Enrollment will last 2.5 years and all women will be followed for 6 years. 60,000 women will be enrolled.

The primary objective is to compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals and this will be evaluated at the end of the 6-year follow-up period.

At the same time, data from all women registered in screening archives who have had a negative mammogram at the age of 69-71 years will be collected and analyzed. The data will be retrieved up to the age of 78 and will concern screening mammograms as well as other screening procedures (e.g. biopsies) and also mammograms performed outside the program. Data from screening and outpatient information systems as well as from cancer registries will be used.

To identify the best strategy to communicate changes in screening protocols, especially when the new protocol would be less intensive than the actual one, a qualitative research will be conducted. In particular the following steps will be considered:

  • Focus groups for discussing, with women from target population and health care professionals, key arguments identified in a preliminary research (i.e. scientific literature and case-studies research), with particular focus on how they should be translated into communication strategies.
  • Pre-test of the study's communication material through web-based semi-structured interviews to eligible women and key-informants.
  • Assessment of the effectiveness of the communication material through web-based semi-structured interviews to participants, that may bring insights on how planning communication strategies for the implementation of new screening protocols.
Conditions
Breast Cancer
Being tested
screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice
Keywords
Breast cancer, screening, diagnosis, mammography
Medical subject headings
Breast Neoplasms, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practiceDiagnostic test

    women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;

Study groups in NCT04590560
Study groupRoleWhat they receive
1-year screening intervalNo interventionWomen will follow the normal screening program (they will be invited to screen every year)
2-year screening intervalExperimentalWomen will be invited to screen every two years
Receives: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice
3-tailored screening intervalExperimentalthe screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
Receives: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals

    Cumulative breast cancer risk will computed as the ratio between the number of stage 2 or higher cancers and the total number of women in the arm. The comparison between arms will be performed using the two proportion Z-test. 95% confidence intervals will also be computed

    Measured: 6 years

Secondary outcomes (9)
  1. Participation in screening

    number of participating women within 3 months since invitation)/(total invited women). It will be computed for each screening round and overall as average of round participation

    Measured: 6 years

  2. contamination proportion (use of mammography) within two screening rounds (in women referred to 2-year interval)

    number of women referred to 2-year interval and performing a mammogram within two screening round)/number of women referred to 2-year interval The indicator will be computed only for women randomized to arm 2 and for women referred to 2-year arm in arm 3

    Measured: 6 years

  3. Breast cancer detection

    number of women with BC diagnosis at screening / number of total screened women

    Measured: 6 years

  4. overall recall rate

    number of women recalled for further assessment/ number of total screened women.

    Measured: 6 years

  5. rate of recall with an invasive procedure (biopsy)

    number of women recalled for further assessment with a biopsy/ number of total screened women

    Measured: 6 years

  6. interval Breast Cancer rate

    number of cancers occurring after a negative mammography and before the date of the next planned appointment/ number of total screened women

    Measured: 6 years

  7. cumulative Breast Cancer incidence

    Cumulative incidence of BC including baseline test

    Measured: 6 years

  8. resource expenditure

    Mean costs for each attending woman in every of the following processes:

    Coordination and organization; Invitation; First level mammography; Diagnostic assessment (invasive and non invasive)

    Measured: 6 years

  9. prevalence of dense breast in the target population

    women with BI-RADS A, B, C, and D/total women included in the tailored arm

    Measured: 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2020
  2. Study start6 Feb 2020
  3. Primary completionFeb 2026 (estimated)
  4. Study completionFeb 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Eligible women signing the written informed consent will be randomized with a 1:1:1 ratio to: Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C).
Masking
None (open label)
Enrolment
60,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04590560
Sponsor's protocol ID
IRST174.22
Acronym
MISS
Status last verified
Dec 2024
First submitted
12 Oct 2020
Last updated
9 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice in people with Breast Cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS at 4 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Oriana Nanni (+39 0543 739100, oriana.nanni@irst.emr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals (time frame: 6 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in